Compounds > tug-469
Page last updated: 2024-11-13

tug-469

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

TUG-469: a GPR40 agonist with antidiabetic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46941175
CHEMBL ID1773261
SCHEMBL ID16188922
MeSH IDM000595560

Synonyms (21)

Synonym
CHEMBL1773261 ,
3-(4(2''-methylbiphenyl-3-ylmethylamino)phenyl)propanoic acid
bdbm50343141
3-(4-(((2'-methyl-[1,1'-biphenyl]-3-yl)methyl)amino)phenyl)propanoic acid
tug-469
1236109-67-3
SCHEMBL16188922
Z2327516080
3-[4-[[3-(2-methylphenyl)phenyl]methylamino]phenyl]propanoic acid
EX-A5077
F82333
MS-25305
4-(((2'-methyl(1,1'-biphenyl)-3-yl)methyl)amino)benzenepropanoic acid
unii-gzp4k3i8pa
benzenepropanoic acid, 4-(((2'-methyl(1,1'-biphenyl)-3-yl)methyl)amino)-
gzp4k3i8pa ,
tug469
3-(4-((3-(2-methylphenyl)phenyl)methylamino)phenyl)propanoic acid
HY-123297
CS-0082430
AKOS040754277
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Free fatty acid receptor 1Homo sapiens (human)Ki0.00590.00220.05080.2188AID1308063
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Free fatty acid receptor 1Homo sapiens (human)EC50 (µMol)0.02180.00030.73698.8000AID1308064; AID595115; AID595121; AID595122; AID595166; AID620370; AID673112; AID698539
Free fatty acid receptor 4Homo sapiens (human)EC50 (µMol)6.30960.04372.35477.5858AID673111; AID698535
Free fatty acid receptor 1Mus musculus (house mouse)EC50 (µMol)0.01900.00150.01050.0190AID595171
Muscarinic acetylcholine receptorCavia porcellus (domestic guinea pig)EC50 (µMol)0.01480.00000.89397.8660AID595121
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
phospholipase C-activating G protein-coupled receptor signaling pathwayFree fatty acid receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationFree fatty acid receptor 1Homo sapiens (human)
insulin secretionFree fatty acid receptor 1Homo sapiens (human)
negative regulation of interleukin-1 beta productionFree fatty acid receptor 1Homo sapiens (human)
glucose homeostasisFree fatty acid receptor 1Homo sapiens (human)
positive regulation of calcium ion transportFree fatty acid receptor 1Homo sapiens (human)
response to fatty acidFree fatty acid receptor 1Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayFree fatty acid receptor 1Homo sapiens (human)
ligand-gated ion channel signaling pathwayFree fatty acid receptor 1Homo sapiens (human)
positive regulation of insulin secretionFree fatty acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayFree fatty acid receptor 1Homo sapiens (human)
negative regulation of cytokine productionFree fatty acid receptor 4Homo sapiens (human)
inflammatory responseFree fatty acid receptor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayFree fatty acid receptor 4Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayFree fatty acid receptor 4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationFree fatty acid receptor 4Homo sapiens (human)
regulation of glucose transmembrane transportFree fatty acid receptor 4Homo sapiens (human)
negative regulation of interleukin-1 beta productionFree fatty acid receptor 4Homo sapiens (human)
ghrelin secretionFree fatty acid receptor 4Homo sapiens (human)
negative regulation of apoptotic processFree fatty acid receptor 4Homo sapiens (human)
positive regulation of osteoblast differentiationFree fatty acid receptor 4Homo sapiens (human)
negative regulation of inflammatory responseFree fatty acid receptor 4Homo sapiens (human)
white fat cell differentiationFree fatty acid receptor 4Homo sapiens (human)
brown fat cell differentiationFree fatty acid receptor 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of tasteFree fatty acid receptor 4Homo sapiens (human)
positive regulation of glucagon secretionFree fatty acid receptor 4Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeFree fatty acid receptor 4Homo sapiens (human)
negative regulation of somatostatin secretionFree fatty acid receptor 4Homo sapiens (human)
positive regulation of brown fat cell differentiationFree fatty acid receptor 4Homo sapiens (human)
positive regulation of cold-induced thermogenesisFree fatty acid receptor 4Homo sapiens (human)
cellular response to hormone stimulusFree fatty acid receptor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayFree fatty acid receptor 4Homo sapiens (human)
hormone secretionFree fatty acid receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityFree fatty acid receptor 1Homo sapiens (human)
lipid bindingFree fatty acid receptor 1Homo sapiens (human)
bioactive lipid receptor activityFree fatty acid receptor 1Homo sapiens (human)
G protein-coupled receptor activityFree fatty acid receptor 4Homo sapiens (human)
fatty acid bindingFree fatty acid receptor 4Homo sapiens (human)
taste receptor activityFree fatty acid receptor 4Homo sapiens (human)
peptide bindingFree fatty acid receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneFree fatty acid receptor 1Homo sapiens (human)
plasma membraneFree fatty acid receptor 1Homo sapiens (human)
lysosomal membraneFree fatty acid receptor 4Homo sapiens (human)
plasma membraneFree fatty acid receptor 4Homo sapiens (human)
ciliumFree fatty acid receptor 4Homo sapiens (human)
endosome membraneFree fatty acid receptor 4Homo sapiens (human)
endocytic vesicleFree fatty acid receptor 4Homo sapiens (human)
ciliary membraneFree fatty acid receptor 4Homo sapiens (human)
plasma membraneFree fatty acid receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID698522Tmax in C57bl/6 mouse at 10 mg/kg, po2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
AID595116Agonist activity at human FFA1 transfected in 1321N1 cells assessed as calcium mobilization by microplate assay relative to 10 uM TUG-202010ACS medicinal chemistry letters, Oct-14, Volume: 1, Issue:7
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
AID698523Cmax in C57bl/6 mouse at 10 mg/kg, po2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
AID595115Agonist activity at human FFA1 transfected in 1321N1 cells assessed as calcium mobilization by microplate assay2010ACS medicinal chemistry letters, Oct-14, Volume: 1, Issue:7
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
AID673112Agonist activity at FFAR1 expressed in HEK 293 cells assessed as beta-arrestin recruitment after 30 mins by BRET assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Discovery of a potent and selective GPR120 agonist.
AID1308063Displacement of 3-(2-Fluoro-4-((2'-methyl-4'-(2-(2-((7-nitrobenzo[c][1,2,5]-oxadiazol-4-yl)amino)ethoxy)ethoxy)-[1,1'-biphenyl]-3-yl)-methoxy)phenyl)propanoic acid from N-terminal NLUC-tagged FFA1 receptor (unknown origin) expressed in human Flp-In T-REX-2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer.
AID595122Agonist activity at human FFA1 transfected in 1321N1 cells assessed as calcium mobilization by microplate assay in presence of 0.5 % bovine serum albumin2010ACS medicinal chemistry letters, Oct-14, Volume: 1, Issue:7
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
AID673111Agonist activity at GPR120 expressed in HEK 293 cells assessed as beta-arrestin recruitment after 5 mins by BRET assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Discovery of a potent and selective GPR120 agonist.
AID620370Agonist activity at human FFA1 receptor expressed in human 1321N1 cells assessed as calcium mobilization by fluorescence spectrophotometry2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
AID673123Agonist activity at GPR120 expressed in HEK 293 cells assessed as beta-arrestin recruitment after 5 mins by BRET assay relative to TUG-4242012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Discovery of a potent and selective GPR120 agonist.
AID698530Stability in human liver microsomes at 1 uM incubated for 60 mins by HPLC-MS/MS method2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
AID595119Transactivation of human PPARgamma ligand binding domain transfected in mouse embryo fibroblasts assessed as renilla luciferase activity at 1 uM after 18 hrs by luminometry relative to 1 uM rosiglitazone2010ACS medicinal chemistry letters, Oct-14, Volume: 1, Issue:7
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
AID698539Agonist activity at human GPR40 expressed in Flp-InTM T-RexTM HEK293 cells assessed as stimulation of calcium mobilization2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
AID595117Transactivation of human PPARgamma ligand binding domain transfected in mouse embryo fibroblasts at 100 uM after 18 hrs analyzed by photinus and renilla luciferase activity by luminometry relative to 1 uM rosiglitazone2010ACS medicinal chemistry letters, Oct-14, Volume: 1, Issue:7
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
AID595170Agonist activity at human GPR41 in HEK293 cells2010ACS medicinal chemistry letters, Oct-14, Volume: 1, Issue:7
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
AID595121Agonist activity at human FFA1 transfected in 1321N1 cells assessed as calcium mobilization by microplate assay in presence of 0.05 % bovine serum albumin2010ACS medicinal chemistry letters, Oct-14, Volume: 1, Issue:7
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
AID698533Lipophilicity, log D of the compound at pH 7.4 by shake flask method2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
AID698535Agonist activity at GPR120 assessed as stimulation of calcium mobilization2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
AID595123Induction of 12 mM glucose-stimulated insulin secretion in rat INS-1E cells at 10 uM after 1 hr by radioimmunoassay2010ACS medicinal chemistry letters, Oct-14, Volume: 1, Issue:7
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
AID698521AUC in C57bl/6 mouse at 10 mg/kg, po2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
AID673122Agonist activity at FFAR1 expressed in HEK 293 cells assessed as beta-arrestin recruitment after 30 mins by BRET assay relative to TUG-4242012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Discovery of a potent and selective GPR120 agonist.
AID595114Agonist activity at human FFA1 transfected in 1321N1 cells under serum-free condition up to 1 hr by dynamic mass redistribution optical biosensor assay2010ACS medicinal chemistry letters, Oct-14, Volume: 1, Issue:7
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
AID1308064Agonist activity at human C-terminal eYFP-tagged FFA1 receptor expressed in HEK-293 cells assessed as beta-arrestin2 recruitment incubated for 5 mins by BRET assay2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer.
AID698532Agonist activity at GPR120 assessed as stimulation of calcium mobilization relative to TUG202012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
AID595171Activation of FFA1 in mouse islets assessed as glucose-dependent insulin secretion2010ACS medicinal chemistry letters, Oct-14, Volume: 1, Issue:7
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
AID595169Agonist activity at human GPR43 in HEK293 cells2010ACS medicinal chemistry letters, Oct-14, Volume: 1, Issue:7
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
AID595165Induction of 2.8 mM glucose-stimulated insulin secretion in rat INS-1E cells at 10 uM after 1 hr by radioimmunoassay2010ACS medicinal chemistry letters, Oct-14, Volume: 1, Issue:7
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
AID1308065Agonist activity at human C-terminal eYFP-tagged FFA1 receptor expressed in HEK-293 cells assessed as beta-arrestin2 recruitment incubated for 5 mins by BRET assay relative to TUG-7702016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer.
AID698538Agonist activity at human GPR40 expressed in Flp-InTM T-RexTM HEK293 cells assessed as stimulation of calcium mobilization relative to TUG202012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
AID595166Agonist activity at human FFA1 transfected in 1321N1 cells under serum-free condition after 1 hr by dose response curve/dynamic mass redistribution optical biosensor assay2010ACS medicinal chemistry letters, Oct-14, Volume: 1, Issue:7
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
AID595120Selectivity for human FFA1 over human PPARgamma2010ACS medicinal chemistry letters, Oct-14, Volume: 1, Issue:7
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (90.91)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.21 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index5.70 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ketoprofen
Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.		2.0610benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
lauric acid
dodecanoic acid : A straight-chain, twelve-carbon medium-chain saturated fatty acid with strong bactericidal properties; the main fatty acid in coconut oil and palm kernel oil.		2.1310medium-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
antibacterial agent;
plant metabolite
pd 98059
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.		2.1110aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.1510pyrrole;
secondary amine
colforsin
Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.		2.1510acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
alpha-linolenic acid
linolenic acid : A two-membered subclass of octadecatrienoic acid comprising the (9Z,12Z,15Z)- and (6Z,9Z,12Z)-isomers. Linolenic acids are nutrients essential to the formation of prostaglandins and are also used in making paints and synthetic resins.. linolenate : A polyunsaturated fatty acid anion obtained by deprotonation of the carboxy group of either alpha- or gamma-linolenic acid.		2.0710linolenic acid;
omega-3 fatty acid		micronutrient;
mouse metabolite;
nutraceutical
su 11248
[no description available]		2.1510monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
gw9508
GW9508: structure in first source		3.1750aromatic amine
tak-875
[no description available]		2.4920biphenyls
amg-837
AMG-837: GPR40 agonist		2.4920
tug-891
GPU-028: structure in first source		2.0710
ConditionIndicatedRelationship StrengthStudiesTrials
Diabetes Mellitus, Adult-Onset
[description not available]		02.4720
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.4720
Impaired Glucose Tolerance
[description not available]		02.1510
Liver Steatosis
[description not available]		02.1510
Insulin Sensitivity
[description not available]		02.1510
Fatty Liver
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.		02.1510
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		02.1510
Glucose Intolerance
A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.		02.1510
Adenoma, beta-Cell
[description not available]		02.2510
Insulinoma
A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0810
Prediabetes
[description not available]		02.0810
Prediabetic State
The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).		02.0810